专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2005058290A2 USE OF VITAMIN E 审中-公开
标题翻译：维生素E的使用
公开(公告)号：WO2005058290A2
公开(公告)日：2005-06-30
申请号：PCT/EP2004014000
申请日：2004-12-09
申请人： DSM IP ASSETS BV , BARELLA LUCA , RIMBACH GERALD
发明人： BARELLA LUCA , RIMBACH GERALD
IPC分类号： A23L33/15 , A61K31/355 , A61K31/4045 , A61K31/00
CPC分类号： A61K31/355 , A61K31/4045 , A61K2300/00
摘要： Vitamin E is useful for facilitating the synchronization of circadian rhythm in humans, especially for treatment or prevention of jet lag.
摘要翻译：维生素E有助于促进人类昼夜节律的同步，特别是治疗或预防时差。

2. 发明申请

WO2006094678A3 METHOD FOR MEASURING AND COMPARING THE ACTIVITY OF BIOLOGICALLY ACTIVE COMPOUNDS 审中-公开
标题翻译：用于测量和比较生物活性化合物活性的方法
公开(公告)号：WO2006094678A3
公开(公告)日：2006-11-16
申请号：PCT/EP2006001811
申请日：2006-02-28
申请人： DSM IP ASSETS BV , BARELLA LUCA , MULLER PATRICK Y , NETSCHER THOMAS , STOECKLIN ELISABETH
发明人： BARELLA LUCA , MULLER PATRICK Y , NETSCHER THOMAS , STOECKLIN ELISABETH
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6876 , C12Q2600/136 , C12Q2600/158
摘要： Biologically active compounds (e.g. from the groups of pharmaceutical drugs, cofactors, hormones, vitamins or phytochemicals) often consist of two or more stereoisomers (enantiomers or diastereoisomers) which may differ in their pharmacodynamic/kinetic, toxicological and biological properties. These differences are so far difficult to detect. A well known example for a biologically active compound and its counterpart is vitamin E which is predominantly administered as two different "forms", one derived from natural sources (mainly soybeans), and one from production by chemical total-synthesis. While vitamin E from natural sources occurs as a single stereoisomer (RRR-a-tocopherol), so-called synthetic vitamin E (all-rac-a-tocopherol) is an equimolar mixture of eight stereoisomers. The present invention is directed to a method for calculating the biological activity of a biologically active compound (e.g. RRR-a-tocopherol) and a counterpart thereof (e.g. all-rac-a-tocopherol), comprising the steps of: culturing a plurality of cells in a culture medium and treating the cells with different concentrations of either said compound or said counterpart thereof; or treating a plurality of animals or plants with different concentrations of either said compound or said counterpart; preparing samples from the treated cells or animals or plants containing a pool of target nucleic acids comprising RNA transcripts; detecting the expression of genes in said cells by measuring the amount of transcripts of said genes to obtain a target expression pattern by hybridizing said pool of target nucleic acids to an array of nucleic acid probes immobilized on a surface, wherein said array comprising at least 10 different nucleic acids, some of which comprise control probes, and wherein each different nucleic acid is localized in a known location of said surface; quantifying the hybridization of said nucleic acids to said array by comparing binding of matched and control probes; calculating the biological activity of the compound and its counterpart therefrom.
摘要翻译：生物活性化合物（例如来自药物，辅因子，激素，维生素或植物化学物质的组）通常由它们的药效/动力学，毒理学和生物学特性可能不同的两种或更多种立体异构体（对映异构体或非对映异构体）组成。这些差异到目前为止难以发现。生物活性化合物及其对应物的众所周知的实例是维生素E，其主要以两种不同的“形式”施用，一种衍生自天然来源（主要是大豆），一种来自通过化学全合成生产。虽然来自天然来源的维生素E作为单一立体异构体（RRR-α-生育酚）发生，所谓的合成维生素E（全消旋-α-生育酚）是八种立体异构体的等摩尔混合物。本发明涉及计算生物活性化合物（例如RRR-α-生育酚）及其对应物（例如全消旋-α-生育酚）的生物活性的方法，包括以下步骤：培养多培养基中的细胞并用不同浓度的所述化合物或其对应物处理细胞; 或处理具有不同浓度的所述化合物或所述对应物的多种动物或植物; 从处理的细胞或包含含有RNA转录物的靶核酸池的动物或植物制备样品; 通过测量所述基因的转录物的量来测量所述基因的转录物的量，以通过将所述靶核酸库与固定在表面上的核酸探针阵列进行杂交来检测所述基因的转录物的量，其中所述阵列包含至少10个不同的核酸，其中一些核酸包含对照探针，并且其中每个不同的核酸定位在所述表面的已知位置; 通过比较匹配和对照探针的结合来定量所述核酸与所述阵列的杂交; 计算化合物及其对应物的生物活性。

3. 发明专利

DE60328517D1 未知
公开(公告)号：DE60328517D1
公开(公告)日：2009-09-03
申请号：DE60328517
申请日：2003-12-04
申请人： DSM IP ASSETS BV
发明人： BARELLA LUCA , GORALCZYK REGINA , SILER ULRICH , WERTZ KARIN
IPC分类号： A61K31/01 , A61K31/07 , A61K31/353 , A61K31/355 , A61K31/375 , A61P5/00
摘要： Lycopene can be used in the primary prevention and incidence risk reduction of non-cancerous symptoms and/or pathologies (i.e., the prophylactic supplementation of the healthy subjects), in the treatment or the coadjuvant treatment of non-can-cerous symptoms and/or pathologies (i.e. the supplementation as therapy or accompanying a running therapy) and in the secondary prevention of non-cancerous symptoms and/or pahtologies (i.e., the supplementation after a successful therapy for the prevention of the relapse), which are associated with, favored by or caused by androgen signalling or which are sensitive to a reduction of androgen signalling.

4. 发明专利

AU2003294778A1 NOVEL USE OF LYCOPENE 未知
公开(公告)号：AU2003294778A1
公开(公告)日：2004-06-30
申请号：AU2003294778
申请日：2003-12-04
申请人： DSM IP ASSETS BV
发明人： WERTZ KARIN , BARELLA LUCA , GORALCZYK REGINA , SILER ULRICH
IPC分类号： A61K31/01 , A61K31/07 , A61K31/353 , A61K31/355 , A61K31/375
摘要： Lycopene can be used in the primary prevention and incidence risk reduction of non-cancerous symptoms and/or pathologies (i.e., the prophylactic supplementation of the healthy subjects), in the treatment or the coadjuvant treatment of non-can-cerous symptoms and/or pathologies (i.e. the supplementation as therapy or accompanying a running therapy) and in the secondary prevention of non-cancerous symptoms and/or pahtologies (i.e., the supplementation after a successful therapy for the prevention of the relapse), which are associated with, favored by or caused by androgen signalling or which are sensitive to a reduction of androgen signalling.

5. 发明专利

ES2329238T3 NUEVO USO DE LICOPENO PARA EL TRATAMIENTO DE ENFERMEDADES ASOCIADAS CON LA SEÑALIZACION DE ANDROGENOS. 未知
公开(公告)号：ES2329238T3
公开(公告)日：2009-11-24
申请号：ES03785727
申请日：2003-12-04
申请人： DSM IP ASSETS BV
发明人： BARELLA LUCA , GORALCZYK REGINA , SILER ULRICH , WERTZ KARIN
IPC分类号： A61K31/01 , A61K31/07 , A61K31/353 , A61K31/355 , A61K31/375 , A61P5/00
摘要： El uso de licopeno en la fabricación de una composición para la prevención primaria y secundaria, la reducción del riesgo de incidencia, el tratamiento coadyuvante o el tratamiento de síntomas y/o patologías no cancerosos, que están asociados con, favorecidos o causados por señalización de andrógenos, o que son sensibles a una reducción de la señalización de andrógenos, en donde los síntomas y/o patologías se seleccionan del grupo constituido por: síndrome de ovario poliquístico, anovulación crónica hiperandrogénica, infertilidad femenina, síndrome de hiperestimulación ovárica, amenorrea, oligomenorrea, obesidad, acumulación de grasa abdominal, hirsutismo, trastorno menstrual, hiperandrogenismo, hiperplasia suprarrenal congénita (CAH) y desequilibrio de la señalización de andrógenos inducido por estrés.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式